中成药金振口服液联合头孢噻肟钠治疗小儿咳嗽病（痰热证）的临床研究

Objective To investigate the effect of the treatment in children with phlegm-heat syndrome by the combination of Jinzhen Oral Liquid and cefotaxime sodium. Methods A total of 80 children with cough (phlegm-heat syndrome) who were treated in our hospital from April 2023 to April 2025 were divided by random number table method, 40 cases in the control group were treated with cefotaxime sodium, and 40 cases in the experimental group were treated with Jinzhen Oral Liquid combined with cefotaxime sodium. The symptom scores, inflammatory indices, improvement time, therapeutic efficacy and incidence of adverse reactions were compared and analyzed. Results Compared with symptom scores, the total score of experimental group was lower than that of control group (P＜0.05). Compared with the inflammatory indices, the experimental groups were lower than the control group after treatment (P＜0.05). The improvement time of experimental group was shorter than that of control group (P＜0.05). The total effective rate of experimental group (97.50%) was better than that of control group (82.50%) (P＜0.05). The incidence of adverse reactions was compared. The difference between the experimental group (10.00%) and the control group (5.00%) was small and not statistically significant (P＞0.05). Conclusion The effects achieved by children with cough due to phlegm-teat syndrome treated with oral administration of the medicine Jinzhen Oral Liquid and intravenous drip of cefotaxime sodium are definite. It is conducive to symptom relief, inflammatory index improvement, short improvement time, and less adverse reaction.